Solid Bio and Phlox team up in rare cardiac diseases

12 January 2023

US neuromuscular and cardiac diseases specialist Solid Biosciences (Nasdaq: SLDB) and privately-held Dutch biotech Phlox Therapeutics have announced a strategic collaboration focused on genetic cardiac diseases.

They will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments.

Solid’s vector biology, manufacturing capabilities and drug development experience will be integrated with Phlox’s deep expertise in genetic cardiomyopathies and RNA therapeutics. The companies will collaborate to develop novel precision genetic medicines for this form of DCM.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK